To the Editors:
We have read with interest recent reports on the complex interactions between Aspergillus fumigatus and the lungs [1–3]. A. fumigatus may be involved in different respiratory diseases including aspergilloma, allergic bronchopulmonary aspergillosis (ABPA) or invasive infectious manifestations. However, these different manifestations are usually not concomitantly present and there are only a few studies that report the association between these complications [4–14]. We wish to present a case of fully documented aspergilloma and ABPA in a patient with difficult asthma, which represented a difficult therapeutic challenge.
A 50-yr-old female, nonsmoker was followed up since 2000 for difficult to control non-atopic asthma associated with severe rhinosinusitis. In March 2008, the patient presented to the respiratory department (Hôpital Antonie Béclère, Clamart, France) with a 1-month history of mild recurrent haemoptysis. Physical examination was normal. Chest radiography showed excavated lung opacity in the superior left field. A thoracic computed tomography (CT) scan revealed a cavity with a fungus ball in the left upper lobe and two other opacities in the left lower lobe (fig. 1). There was no fungus ball in the sinuses. Fiberoptic bronchoscopy showed no abnormality. Bronchial fluid aspiration and bronchoalveolar lavage stains and cultures did not detect either resistant acid alcohol bacilli or Aspergillus. The eosinophil count was 1.5 ×109·L−1 and total serum immunoglobulin (Ig)E levels were elevated (2,236 KU·L−1, normal range: 0–113 KU·L−1). A. fumigatus specific IgE was positive (41.2 KU·L−1). Aspergillus serology including Aspergillus immunoelectrophoresis was positive. Antinuclear antibodies and antineutrophil cytoplasmic antibodies were negative. A CT scan of the chest revealed persistence of the left upper lobe opacity, disappearance of the other opacities and localised bronchiectasis of the left lower lobe. No evidence of transient pulmonary infiltrates has been documented. A diagnosis of concomitant aspergilloma and ABPA was suspected. A wedge resection of the left upper lobe was performed (fig. 2). The histopathological examination of the resected wedge revealed an aspergilloma with fungal hyphae (fig. 3). Culture of this material yielded A. fumigatus. The patient received itraconazole post-operatively at a dose of 300 mg·day−1 and was continued on inhaled corticosteroids. 5 months after the intervention, her total serum IgE count dropped to 1,769 KU·L−1 and her A. fumigatus specific IgE level dropped to 33.8 KU·L−1. 2 yrs after surgery the patient remains asymptomatic with a normal thoracic CT apart from localised bronchiectasis of the left lower lobe. Itraconazole was discontinued after 18 months of treatment.
Thoracic computed tomography revealing a 16-mm cavity with a fungus ball in the anterior segment of the left upper lobe (a), and two other lesions of the left apical segment and the left lower lobe measuring 9 mm and 19 mm (b), respectively.
Macroscopic examination of the wedge resected lung revealing a 12 mm aspergilloma with a fungus ball.
Histological examination (Haematoxylin-eosin staining) of the pulmonary aspergilloma. a) A dilated bronchus filled with necrosed aspergillus hyphae. The small airway is apparently connected to the main cavity (top left). b) Partially necrosed masses of hyphae within the cavity and the so-called fungus ball (left). Note the granulation tissue of the cavity wall, consisting of fibroblasts and inflammatory cells that are mainly lymphocytes, plasma cells and eosinophil leukocytes. Scale bars = 100 μm.
A. fumigatus may cause significant morbidity in the respiratory tract (aspergilloma, ABPA and invasive infectious manifestations). Classically, only one disease occurs in each patient. However, there are a few case reports of the association between these complications [2, 3, 9–11, 14, 15]. Aspergilloma is a fungus ball caused by saprophytic overgrowth of Aspergillus species in a cavitary or cystic lung disease. However, tissue necrosis and invasion of blood vessels does not occur. Aspergilloma is an unusual complication of ABPA [9]. The mechanism by which this occurs is by focal dilatation of the ectatic bronchi, due to accumulation of material produced during the immune response to Aspergillus. The cavity can then be colonised by Aspergillus species to form an aspergilloma. In such cases aspergilloma formation is thought to be accelerated by corticosteroids [16].
In our patient, we made the diagnosis of concomitant aspergilloma and ABPA. As was observed in our patient, patients with ABPA often present with poorly controlled asthma and peripheral eosinophilia, and exhibit exacerbations followed by remissions when receiving systemic corticosteroid therapy. The association of ABPA and aspergilloma may present a real therapeutic challenge due to the central role of corticosteroids in the management of ABPA and the possible risk of aspergilloma growth with corticosteroid therapy. Only a few studies have demonstrated the role of intraconazole in improving asthma in ABPA regardless of corticosteroid therapy [17, 18]. Medical treatment is unable to cure this condition and surgery remains the treatment of choice for aspergilloma became of the risk of unpredictable life-threatening haemoptysis. Our patient underwent a wedge resection as the rest of the parenchyma was normal. She received itraconazole and inhaled corticosteroids as she had superimposed ABPA, with a favourable outcome. This case highlights that the association of aspergilloma and ABPA is rare but possible.
Footnotes
Provenance
Submitted article, peer reviewed.
Statement of Interest
D. Montani has relationships with drug companies including AB Science, Actelion, Bayer Schering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. M. Humbert has relationships with drug companies including AB Science, Actelion, Bayer Schering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards.
- ©ERS 2010
REFERENCES
